• Submit to Viruses Login Register
• MDPI
• Journals A-Z
• For Authors
• For Editors
• For Librarians
• About
• Open Access Policy

• Abstract
• Full-Text PDF [481 KB]
• Full-Text XML
• Article Versions Notes

• Article Statistics
• PubMed/Medline
• Google Scholar
• Order Reprints

• Cite this article
• Export to BibTeX
• Export to EndNote

• [+] on DOAJ
• DiGiusto, DL.
• Stan, R
• Krishnan, A
• Li, H
• Rossi, JJ.
• Zaia, JA.
• [+] on Google Scholar
• DiGiusto, DL.
• Stan, R
• Krishnan, A
• Li, H
• Rossi, JJ.
• Zaia, JA.
• [+] on PubMed
• DiGiusto, DL.
• Stan, R
• Krishnan, A
• Li, H
• Rossi, JJ.
• Zaia, JA.

•  CiteULike
•  Facebook
•  Mendeley
•  Twitter
• More services

Open AccessThis article is

• freely available
• re-usable

Viruses 2013, 5(11), 2898-2919; doi:10.3390/v5112898

Article

Development of Hematopoietic Stem Cell Based Gene Therapy for HIV-1 Infection: Considerations for Proof of Concept Studies and Translation to Standard Medical Practice

David L. DiGiusto ^1,* , Rodica Stan ¹, Amrita Krishnan ², Haitang Li ³, John J. Rossi ³ and John A. Zaia ¹

¹ Department of Virology, Beckman Research Institute of the City of Hope, 1500 East Duarte Road, Duarte, CA 91010, USA ² Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, 1500 East Duarte Road, Duarte, CA 91010, USA ³ Department of Molecular and Cellular Biology, Beckman Research Institute of the City of Hope, 1500 East Duarte Road, Duarte, CA 91010, USA

* Author to whom correspondence should be addressed.

Received: 18 October 2013; in revised form: 15 November 2013 / Accepted: 18 November 2013 / Published: 22 November 2013

(This article belongs to the Special Issue Gene Therapy for Retroviral Infections)

Download PDF Full-Text [481 KB, uploaded 22 November 2013 12:50 CET]

Abstract: Over the past 15 years we have been investigating an alternative approach to treating HIV-1/AIDS, based on the creation of a disease-resistant immune system through transplantation of autologous, gene-modified (HIV-1-resistant) hematopoietic stem and progenitor cells (GM-HSPC). We propose that the expression of selected RNA-based HIV-1 inhibitors in the CD4+ cells derived from GM-HSPC will protect them from HIV-1 infection and results in a sufficient immune repertoire to control HIV-1 viremia resulting in a functional cure for HIV-1/AIDS. Additionally, it is possible that the subset of protected T cells will also be able to facilitate the immune-based elimination of latently infected cells if they can be activated to express viral antigens. Thus, a single dose of disease resistant GM-HSPC could provide an effective treatment for HIV-1+ patients who require (or desire) an alternative to lifelong antiretroviral chemotherapy. We describe herein the results from several pilot clinical studies in HIV-1 patients and our strategies to develop second generation vectors and clinical strategies for HIV-1+ patients with malignancy who require ablative chemotherapy as part of treatment and others without malignancy. The important issues related to stem cell source, patient selection, conditioning regimen and post-infusion correlative studies become increasingly complex and are discussed herein.

Keywords: HIV-1; stem cells; gene therapy; non-ablative conditioning; transplantation

Article Statistics

Citations to this Article

Cite This Article